|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial |
| Tanya Dorff, MD |
| Tanya Dorff joins Alicia Morgans discussing updates to the NCCN guidelines for systemic therapies in the treatment of M1 prostate cancer. Both physicians emphasized a key takeaway from the CARD trial, also demonstrated in the PROfound Study, that back to back AR-targeted therapy, even if separated by docetaxel lacks a durable response. |
|
|
|
|
|
|
|
|
|
|
|
|
Evaluating Circulating Tumor Cells in Patients on the CARD Trial
|
|
Eleni Efstathiou, MD, Ph.D.
|
| In this conversation, Alicia Morgans and Eleni Efstathiou highlight a preplanned biomarker analysis of circulating tumor cells in patients on the CARD trial. This was work that the CARD investigators conducted in collaboration with Epic using their technology.
|
|
|
|
|
|
|
|
|
|
|
|
|
BRCA1/2 and Beyond - Molecular Diagnostic Testing and Treatments with PARP Inhibitors for mCRPC
|
|
Joaquin Mateo, MD, Ph.D.
|
| In this conversation with Alicia Morgans, Joaquin Mateo discusses the practice-changing data we have learned from the PROfound study, which solidifies the importance of precision oncology for our patients.
|
|
|
|
|
|
|
|
|
|
|
|
| Treatment Sequencing in Castrate-Resistant Metastatic Cancer |
| Mark Fleming, MD |
| In this conversation with Charles Ryan, Mark Fleming speaks to the complex therapeutic landscape of treatment sequencing in castrate-resistant prostate cancer and offers guidance in managing treatment sequencing amongst the numerous treatment options in each disease state of advanced prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
| Cabazitaxel Multiple Rechallenge in Metastatic Castration-Resistant Prostate Cancer: A Therapeutic Option to Increase Overall Survival?
|
| Cedric Pobel, MD
|
| Cedric Pobel presents an assessment of the feasibility and efficacy of cabazitaxel multiple rechallenges in patients with mCRPC. Based on the data, repeated rechallenges with cabazitaxel may extend overall survival with manageable toxicities for patients with mCRPC.
|
|
|
|
|
|
|
|
|
|
|
| Biomarker Analysis from a Randomized Phase II Study of Olaparib with or Without Cediranib in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| Rana McKay, MD |
| Rana McKay presents a phase 2 study of olaparib versus olaparib in combination with cediranib, an oral antagonist of VEGF receptors 1-3. The rationale from this study comes from preclinical and clinical studies showing that anti-angiogenic agents can result in a hypoxic tumor environment that downregulates the expression of homologous recombination genes, as well as studies in other cancers showing antitumor activity of cediranib and olaparib in combination. |
|
|
|
|
|
| Concordance of BRCA1 and BRCA2, and ATM Mutations Identified in Matched Tumor Tissue and ctDNA in Men mCRPC Screened in the PROfound Study
|
| Kim Chi, MD FRCRC
|
| Kim Chi presents results of a study that sought to evaluate the reliability of using plasma-based assays to detect deleterious mutations in BRCA1, BRCA2, and ATM (the gene alterations in Cohort A of PROfound). These data may make reliable genomic assessments made via ctDNA in subjects who are either unwilling or unable to undergo metastatic biopsy or who have insufficient tissue from such a biopsy, potentially sparing the expense and possible harm of an invasive procedure.
|
|
|
|
|
|
| Real-World Evidence For Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel: Comparison with the Randomized Clinical Study CARD |
| Ronald de Wit, MD, Ph.D. |
| Ronald de Wit presents the results of an evaluation of a large real-world dataset comparing characteristics of patients receiving cabazitaxel after docetaxel and one androgen-signaling-targeted inhibitor with the CARD-eligible population. |
|
|
|
|
|
| Understanding the Evolving Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes |
| Evan Yu, MD |
| Evan Yu presents on the changing landscape of treatment for men with metastatic castration-resistant prostate cancer (mCRPC). Dr. Yu highlights that genetic testing is recommended for patients with advanced prostate cancer. The approval of PARP inhibitors is expected to benefit patients with DNA repair-deficient tumors through ongoing studies that will assess novel combination approaches including PARP inhibitors, immune checkpoint inhibitors, molecularly targeted therapies, and androgen-axis inhibition. |
|
|
|
|
|
|
